In a significant move, UK-based pharmaceutical giant GlaxoSmithKline (GSK) has sealed a three-year, £2.5 billion deal with Chongqing Zhifei Biological Products Co., aiming to fortify the presence of its shingles
Gain insights into the significance of this partnership,its impact on vaccine distribution in China,and how it contributes to the landscape of global healthcare